Precision-Engineered Enzymes
That Target Bacterial Infections.
EndoPel Biologics is developing a proprietary platform of AI-designed endolysin therapeutics — bacteriophage-derived enzymes engineered to rapidly destroy Staphylococcus pseudintermedius, the leading cause of skin, ear, and wound infections in dogs. Our approach delivers targeted bacterial elimination without contributing to the growing antimicrobial resistance crisis.
Rapid Bactericidal Action
Our AI-engineered endolysins achieve complete bacterial cell lysis in under 5 minutes — eliminating pathogens faster than conventional antibiotics with no observed resistance development.
Species-Specific Targeting
Engineered for precision. Our endolysins selectively target S. pseudintermedius and related staphylococcal pathogens while preserving the beneficial microbiome — a critical advantage over broad-spectrum antibiotics.
AI-Driven Design Platform
Our proprietary computational platform designs novel chimeric endolysin architectures optimized for catalytic efficiency, stability, and therapeutic performance — accelerating the path from discovery to clinic.
Antibiotic-Free Future
With over 90% of canine pyoderma cases currently treated with systemic antibiotics, our topical endolysin formulations offer veterinarians a powerful antibiotic-free alternative aligned with global antimicrobial stewardship guidelines.
Contact Us
Interested in our technology or partnership opportunities? Get in touch and a member of our team will respond promptly.